Table 2.
Summary of analyses for outcome measures 12-month follow-up
| Outcome measures 12-month follow-up | Intervention group | Control group | Effectiveness parameter | 95% Confidence interval | ICC | P-value |
|---|---|---|---|---|---|---|
| Primary outcome | ||||||
| Antipsychotic drugs (at least 1), % (n) | 44.8 (167) | 33.3 (163) | Odds ratio 1.621 | (1.038 to 2.532) | 0.057 | 0.033 |
| Secondary outcomes | ||||||
| Quality of life (QoL-AD)a | ||||||
| Self-assessment, mean (n) | 33.1 (120) | 34.0 (170) | Mean difference -0.9 | (−3.0 to 1.1) | 0.094 | 0.365 |
| Proxy assessment, mean (n) | 30.2 (252) | 31.4 (317) | Mean difference -1.2 | (−3.3 to 0.8) | 0.142 | 0.227 |
| Agitated behaviour (CMAI>25)b, % (n) | 53.9 (373) | 43.0 (488) | Odds ratio 1.547 | (0.863 to 2.772) | 0.131 | 0.141 |
| Psychotropic drugsc (at least 1), % (n) | 55.2 (373) | 53.0 (489) | Odds ratio 1.095 | (0.807 to 1.487) | 0.010 | 0.559 |
| Falls (at least 1), % (n) | 22.0 (373) | 21.5 (488) | Odds ratio 1.028 | (0.679 to 1.556) | 0.022 | 0.897 |
| Physical restraintsd, % (n) | 11.3 (373) | 8.2 (489) | Odds ratio 1.424 | (0.529 to 3.834) | 0.133 | 0.480 |
aQoL-AD: Quality of Life-Alzheimer’s Disease scale (total score ranges from 13 to 52, higher scores indicate better QoL); effect estimation by linear mixed model.
bCMAI: Cohen-Mansfield Agitation Inventory (total score ranges from 25 to 175, higher scores indicate higher frequencies of manifestations).
cAntidepressants, anxiolytics and acetylcholinesterase inhibitors.
dBedrails, fixed tables, belts in bed or chair, other physical restraints.
ICC=intra-class correlation coefficient.